DARE Stock Overview A biopharmaceutical company, identifies, develops, and markets products for women’s health in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Daré Bioscience, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Daré Bioscience Historical stock prices Current Share Price US$2.71 52 Week High US$7.56 52 Week Low US$2.67 Beta 1.27 1 Month Change -14.78% 3 Month Change -16.87% 1 Year Change -31.57% 3 Year Change -89.09% 5 Year Change -72.46% Change since IPO -96.24%
Recent News & Updates
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) Dec 17
Daré Bioscience, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 07
Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC Oct 23 Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC Oct 22
Daré Bioscience, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Aug 05
Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder Jun 24 See more updates
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) Dec 17
Daré Bioscience, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 07
Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC Oct 23 Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC Oct 22
Daré Bioscience, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Aug 05
Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder Jun 24 Daré Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $18.08963 million. May 12
Daré Bioscience, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 Apr 24
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024 Feb 01
Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer Jan 28 Daré Bioscience, Inc. Announces Executive Changes
Daré Bioscience's Common Stock to Be Delisted from Nasdaq Unless the Company Timely Requests A Hearing Before the Nasdaq Hearing Panel Jan 21 Daré Bioscience's Common Stock to Be Delisted from Nasdaq Unless the Company Timely Requests A Hearing Before the Nasdaq Hearing Panel Jan 20
Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study Dec 21
Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1 Dec 07
Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive Dec 04
New major risk - Revenue and earnings growth Nov 12
We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate Nov 07
Daré Bioscience, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Price target decreased by 11% to US$5.33 Sep 07
New major risk - Financial position Aug 14
New major risk - Revenue size Aug 11
Daré Bioscience, Inc. Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth Aug 01
Daré Bioscience Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Jul 24
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully Jul 21
Dare Bioscience, Inc. Announces Additional Positive Data from Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women Jul 12
New minor risk - Profitability Jul 07
Consensus revenue estimates decrease by 18% Jul 06 Daré Bioscience, Inc. Provides Update on Activities to Support Commercial Launch of XACIATO Jul 06
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women Jun 22
Dare Bioscience, Inc. Announces Positive Topline Data from the Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Jun 06
Consensus revenue estimates increase by 29%, EPS downgraded May 18
No longer forecast to breakeven Mar 31
Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth? Mar 12
Price target increased by 13% to US$6.00 Feb 16
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause Jan 28
Daré Bioscience, Inc. Announces Positive Pharmacokinetic Results from the DARE-HRT1 Phase 1 / 2 Study Jan 10
Forecast to breakeven in 2025 Dec 31
Daré Bioscience Receives Non-Compliance Notice From Nasdaq Dec 17
Consensus revenue estimates fall by 38% Dec 14
Consensus forecasts updated Nov 17
Price target decreased to US$5.33 Nov 16
Daré Bioscience, Inc. Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study Nov 15
Daré Bioscience Announces Subject Screening for Phase 2B Respond Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete Nov 02 Daré Announces Topline Results of Its Phase 1/2 Clinical Study of Dare-HRT1
Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms Oct 17
Daré Bioscience, Inc. Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive Oct 11
Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive Oct 10
Daré Bioscience Announces Interim Analysis of Phase 2B Respond Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Aug 30
Dare Bioscience reports positive progress for cream for female sexual arousal disorder Aug 29
Consensus revenue estimates increase by 24% Aug 16
No longer forecast to breakeven Aug 10
Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy Jun 30
Daré Bioscience, Inc., Annual General Meeting, Jul 14, 2022 Jun 25
Consensus revenue estimates increase by 11% May 19
Daré Bioscience, Inc., Annual General Meeting, Jun 23, 2022 May 02
Price target increased to US$8.25 Apr 27
Forecast to breakeven in 2024 Apr 27
Daré Bioscience, Inc. Initiates Phase 1/2 Clinical Study of DARE-HRT1 Apr 13
Consensus revenue estimates increase by 43% Apr 07
Forecast to breakeven in 2024 Apr 02
Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely? Apr 02
Price target increased to US$8.25 Apr 01
No longer forecast to breakeven Mar 31
Diving Back Into Daré Bioscience Again Jan 07
Forecast to breakeven in 2024 Jan 02
Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis Dec 08
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully Nov 26
Daré Bioscience, Inc. Announces NIH Grant Award to Support Development of DARE-LARC1 Sep 29
Daré Bioscience, Inc. Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy Sep 24
Consensus revenue estimates increase to US$5.48m Aug 14
Daré Bioscience, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis Aug 10
Price target increased to US$6.33 Jul 03
Consensus forecasts updated May 16
Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists Apr 28
Daré Bioscience, Inc. Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results At the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists Apr 27
Daré Bioscience's DARE-BV1 shows positive action in late-stage bacterial vaginosis study Apr 26
Consensus forecasts updated Apr 01
Diving Into Daré Bioscience Jan 31
New 90-day high: US$1.54 Jan 15
Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching Dec 22
Daré Bioscience Announces Positive Topline Results from DARE-BVFREE, a Phase 3 Trial of Dare-BV1 in Patients Diagnosed with Bacterial Vaginosis Dec 10
New 90-day high: US$1.23 Nov 19
Analysts lower revenue estimates to US$26.7k Nov 19
Dare Bioscience EPS misses by $0.06 Nov 12
New 90-day low: US$0.98 Oct 29
Price target raised to US$5.63 Sep 11 Shareholder Returns DARE US Pharmaceuticals US Market 7D -14.8% -2.0% -3.5% 1Y -31.6% 7.6% 22.1%
See full shareholder returns
Return vs Market: DARE underperformed the US Market which returned 22.1% over the past year.
Price Volatility Is DARE's price volatile compared to industry and market? DARE volatility DARE Average Weekly Movement 9.1% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: DARE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DARE's weekly volatility has decreased from 15% to 9% over the past year.
About the Company Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women’s health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Show more Daré Bioscience, Inc. Fundamentals Summary How do Daré Bioscience's earnings and revenue compare to its market cap? DARE fundamental statistics Market cap US$25.93m Earnings (TTM ) -US$3.60m Revenue (TTM ) US$1.88m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DARE income statement (TTM ) Revenue US$1.88m Cost of Revenue US$21.65m Gross Profit -US$19.76m Other Expenses -US$16.16m Earnings -US$3.60m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.41 Gross Margin -1,050.56% Net Profit Margin -191.61% Debt/Equity Ratio -302.4%
How did DARE perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 00:38 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Daré Bioscience, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kumaraguru Raja Brookline Capital Markets Brian Kemp Dolliver Brookline Capital Markets Douglas Tsao H.C. Wainwright & Co.
Show 4 more analysts 
